← Leaders
Gregory Oakes
Fulcrum Therapeutics, Inc.
✓ Verified current role· as of 2026-08-17
Gregory Oakes is the CEO of Fulcrum Therapeutics, Inc. (FULC).
Recent developments
AI summary of recent coverageRecent coverage has focused on Fulcrum Therapeutics merging with Slate Medicines in an all-stock transaction backed by $245 million in private placement funding, with the combined entity aiming to advance migraine treatment therapies. The merger is structured as a reverse merger that will result in Slate Medicines becoming a public company on Nasdaq under Fulcrum's ticker.
Summarized from the headlines below; see each source for the full story.
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Gregory Oakes, it will appear here — and tie into the news timeline.
Gregory Oakes: FAQ
- What company does Gregory Oakes lead?
- Gregory Oakes is CEO of Fulcrum Therapeutics, Inc..